Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GLM044
MIFTS: 42

Glomerular Disease

Categories: Nephrological diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Glomerular Disease

About this section

MalaCards integrated aliases for Glomerular Disease:

Name: Glomerular Disease 59 17

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 59  
Rare renal diseases


External Ids:

UMLS via Orphanet 73 C0268731
Orphanet 59 ORPHA93548
Sources

Summaries for Glomerular Disease

About this section
MalaCards based summary : Glomerular Disease is related to membranoproliferative glomerulonephritis and nephrotic syndrome. An important gene associated with Glomerular Disease is COL4A5 (Collagen Type IV Alpha 5 Chain), and among its related pathways/superpathways are Primary Focal Segmental Glomerulosclerosis FSGS and A-beta Pathways: Uptake and Degradation. The drugs Prednisolone phosphate and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and monocytes, and related phenotypes are homeostasis/metabolism and immune system

Sources

Related Diseases for Glomerular Disease

About this section

Diseases in the Glomerular Disease family:

Secondary Glomerular Disease Primary Glomerular Disease

Diseases related to Glomerular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 290)
# Related Disease Score Top Affiliating Genes
1 membranoproliferative glomerulonephritis 31.9 NPHS1 CD79A ALB
2 nephrotic syndrome 31.7 NPHS2 NPHS1 CD2AP ALB
3 nephrotic syndrome, type 6 31.7 NPHS2 NPHS1
4 proliferative glomerulonephritis 31.3 CD79A CCL2
5 familial nephrotic syndrome 31.3 NPHS2 NPHS1 CD2AP
6 denys-drash syndrome 31.2 NPHS2 NPHS1 CD2AP
7 nephrotic syndrome, type 1 31.1 NPHS2 NPHS1 CD2AP
8 frasier syndrome 31.1 NPHS2 NPHS1 CD2AP
9 microvascular complications of diabetes 3 31.1 NPHS1 ALB ACE
10 mesangial proliferative glomerulonephritis 31.1 CD79A CCL2
11 sporadic idiopathic steroid-resistant nephrotic syndrome with focal segmental hyalinosis 30.9 NPHS2 CD2AP
12 crescentic glomerulonephritis 30.8 NPHS2 CCL2
13 membranous nephropathy 30.5 NPHS2 NPHS1 CD79A CD2AP ALB ACE
14 chronic graft versus host disease 30.5 CD79A ALB
15 familial idiopathic steroid-resistant nephrotic syndrome with focal segmental hyalinosis 30.4 NPHS2 NPHS1 CD2AP
16 interstitial nephritis 30.4 ALB ACE
17 diffuse mesangial sclerosis 30.3 NPHS2 NPHS1
18 nail-patella syndrome 30.3 NPHS2 CD2AP
19 acute kidney tubular necrosis 30.2 NAGLU ALB
20 acute proliferative glomerulonephritis 30.2 NPHS1 CCL2
21 anuria 30.1 ALB ACE
22 focal segmental glomerulosclerosis 29.9 NPHS2 NPHS1 COL4A5 CD2AP ALB ACE
23 glomerulonephritis 29.9 NPHS2 NPHS1 COL4A5 CD79A CCL2 ALB
24 bacteriuria 29.8 CD79A CCL2
25 vascular disease 29.8 CCL2 ALB ACE
26 hypertensive nephropathy 29.5 NAGLU ALB ACE
27 nephrosclerosis 29.5 NPHS2 NPHS1 CCL2 ACE
28 pulmonary sarcoidosis 29.4 CCL2 ACE
29 autosomal dominant polycystic kidney disease 29.4 CCL2 ALB ACE
30 lipoid nephrosis 29.4 NPHS2 NPHS1 NAGLU CD79A CD2AP CCL2
31 end stage renal failure 29.3 NPHS2 NPHS1 COL4A5 ALB ACE
32 hypertension, essential 28.7 COL4A5 ALB ACE
33 iga glomerulonephritis 28.7 NPHS2 NPHS1 NAGLU CD79A CCL2 ALB
34 kidney disease 27.8 NPHS2 NPHS1 NAGLU COL4A5 CD2AP CCL2
35 primary glomerular disease 12.4
36 secondary glomerular disease 12.4
37 genetic glomerular disease 12.3
38 immunotactoid glomerulopathy 11.6
39 fibrillary glomerulonephritis 11.6
40 iga nephropathy 1 11.4
41 immunotactoid or fibrillary glomerulopathy 11.4
42 loin pain hematuria syndrome 11.2
43 galloway-mowat syndrome 6 11.0
44 nephronophthisis 11.0
45 rapidly progressive glomerulonephritis 10.9
46 c3 glomerulopathy 10.8
47 systemic lupus erythematosus 10.7
48 glomerulopathy with fibronectin deposits 2 10.6
49 lipoprotein glomerulopathy 10.6
50 cfhr5 deficiency 10.6

Graphical network of the top 20 diseases related to Glomerular Disease:



Diseases related to Glomerular Disease
Sources

Symptoms & Phenotypes for Glomerular Disease

About this section

MGI Mouse Phenotypes related to Glomerular Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.92 ACE ALB CD2AP CD79A COL4A5 KLF15
2 immune system MP:0005387 9.8 ACE CCL2 CD2AP CD79A COL4A5 KLF15
3 mortality/aging MP:0010768 9.56 ACE ALB CD2AP COL4A5 KLF15 NAGLU
4 liver/biliary system MP:0005370 9.55 ACE ALB CD79A KLF15 NAGLU
5 renal/urinary system MP:0005367 9.28 ACE ALB CD2AP CD79A COL4A5 KLF15
Sources

Drugs & Therapeutics for Glomerular Disease

About this section

Drugs for Glomerular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
2
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
3
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
4
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
5
Atorvastatin Approved Phase 4 134523-00-5 60823
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
7
Losartan Approved Phase 4 114798-26-4 3961
8
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
9
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
10
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
11
Uric acid Investigational Phase 4 69-93-2 1175
12 Immunoglobulin A Phase 4
13 Cassava Phase 4
14 Methylprednisolone Acetate Phase 4
15 Prednisolone acetate Phase 4
16 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
17 Lipid Regulating Agents Phase 4
18 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
19 Hypolipidemic Agents Phase 4
20 Anticholesteremic Agents Phase 4
21 Antioxidants Phase 4
22 Protective Agents Phase 4
23 Calcineurin Inhibitors Phase 4
24 Antihypertensive Agents Phase 4
25 Angiotensinogen Phase 4
26 Angiotensin II Type 1 Receptor Blockers Phase 4
27 Giapreza Phase 4
28 Angiotensin Receptor Antagonists Phase 4
29 Anti-Arrhythmia Agents Phase 4
30 Sodium Chloride Symporter Inhibitors Phase 4
31 Natriuretic Agents Phase 4
32 diuretics Phase 4
33 Vasoconstrictor Agents Phase 4
34
Epoprostenol Approved Phase 2, Phase 3 35121-78-9, 61849-14-7 5282411 5280427
35
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
36
rituximab Approved Phase 3 174722-31-7 10201696
37
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
38
Mycophenolic acid Approved Phase 3 24280-93-1 446541
39
Azathioprine Approved Phase 3 446-86-6 2265
40 Tezosentan Investigational Phase 2, Phase 3 180384-57-0
41 Beraprost Investigational Phase 2, Phase 3 88430-50-6
42 Platelet Aggregation Inhibitors Phase 2, Phase 3
43 Vasodilator Agents Phase 2, Phase 3
44 Alkylating Agents Phase 3
45 Gastrointestinal Agents Phase 3
46 Antiemetics Phase 3
47 Neuroprotective Agents Phase 3
48 Peripheral Nervous System Agents Phase 3
49 Autonomic Agents Phase 3
50 Antineoplastic Agents, Alkylating Phase 3

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 Treatment of Nephrotic Syndrome Relapse With Low Steroid Dose Unknown status NCT02216747 Phase 4 prednisone 60 mg/meter square Body Surface Area;prednisone 45 mg;prednisone 30 mg
2 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
3 Study of Safety, Immunogenicity and Immunological Memory of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome Unknown status NCT01346007 Phase 4
4 The Renal Protective Effects of Low-dose and High-dose Atorvastatin in Patients With Glomerular Disease and Proteinuria: a Randomized Controlled Double Blinded Study Completed NCT00768638 Phase 4 Atorvastatin;Atorvastatin
5 Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 DiabetesL a Open-label Trial Completed NCT02502071 Phase 4 sodium bicarbonate
6 Study of Tacrolimus vs Mycophenolate Mofetil in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome: a Randomized, Multicenter, Open-label, Parallel-arm Study Not yet recruiting NCT04048161 Phase 4 Tacrolimus;Mycophenolate Mofetil
7 Specific Blockage of Angiotensine 2 and Podocyturia in Glomerular Nephropathies With Hypertension and Proteinuria Suspended NCT00369538 Phase 4 losartan, hydrochlorothiazide;hydrochlorothiazide, losartan
8 TRK-100STP PhaseIIb/III Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis) Completed NCT01090037 Phase 2, Phase 3 TRK-100STP high dose;TRK-100STP low dose;Placebo
9 The Use of Rituximab in the Treatment of Idiopathic Membranous Nephropathy Completed NCT00425217 Phase 2, Phase 3 Rituximab
10 A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy Active, not recruiting NCT03018535 Phase 3 Rituximab;Methylprednisolone;Cyclophosphamide
11 Effect of Rituximab in Treatment of Primary Membranoproliferative Glomerulonephritis Not yet recruiting NCT03180723 Phase 3 Rituximab;Cyclosporin
12 A Randomized, Multicenter Study to Assess the Efficacy on Diseases Activity of Enteric-coated Mycophenolate Sodium Versus Continuation of Azathioprine in Patients With Systemic Lupus Erythematosus on Azathioprine Maintenance Therapy. Terminated NCT00504244 Phase 3 switch to Myfortic;continuation of azathioprine
13 A Double Blind Clinical Trial to Examine the Renal Effects of an Angiotensin Converting Enzyme Inhibitor (Enalapril) in Adults With Chronic Kidney Disease of Uncertain Aetiology (CKDu) Unknown status NCT01624064 Phase 1, Phase 2 Enalapril;Calcium Supplement
14 TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis) Completed NCT02480751 Phase 2 Beraprost;Placebo
15 Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease Recruiting NCT03865407 Phase 2 Allopurinol
16 Rituximab From the First Episode of Minimal Change Nephrotic Syndrome for Preventing Relapse Risk in Adult Patients: a Multicenter Randomized Controlled Trial Not yet recruiting NCT03970577 Phase 2 Rituximab;Prednisone
17 Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis Completed NCT00275613 Phase 1 Rituximab
18 Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy Completed NCT01221181 Phase 1 Eculizumab
19 Pilot Study of Mycophenolate Mofetil in Congenital Uropathies Completed NCT00193635 Phase 1 mycophenolate mofetil
20 A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VIS649 Administered Intravenously in Healthy Subjects Recruiting NCT03719443 Phase 1
21 Steroid Treatment of Childhood Idiopathic Nephrotic Syndrome: Epidemiology, Therapeutic Adequacy, Medium and Long Term Outcomes. A Prospective Observational Cohort Study. Unknown status NCT01386957
22 Interest to Perform a Renal Biopsy Early in the Course of the Henoch-Schoenlein Nephritis Unknown status NCT02811770
23 Pilot Study: Efficacy and Safety of Vitamin D Supplementation in Glomerular Disease Completed NCT01835639
24 Histological and Clinical Biomarkers to Predict the Progression of IgA Nephropathy Completed NCT02529722
25 Kidney Disease Biomarkers Completed NCT00255398
26 Lupus Nephritis: Role of Environmental and Occupational Exposures Completed NCT00342329
27 Prospective Evaluation of Albuminuria in HIV Positive Patients Completed NCT00524992
28 Correlation Between the Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma. Completed NCT01572857
29 Rituximab in the Treatment of Idiopathic Membranous Nephropathy Completed NCT00405340 Early Phase 1 Rituximab
30 Multicenter Prospective Cohort of Kidney Biopsy for Glomerular Disease Research Recruiting NCT03929887
31 Epigenetic Contribution to the Pathogenesis of Diabetic Nephropathy in Qatari Population Recruiting NCT02316522
32 Nephrologic Intervention in Patients Waiting for Cardiac Surgery Recruiting NCT02643745
33 Identification of Patients With High Probability of Not or Poorly Responding to Mycophenolate-mofetil (Cellcept®) or Mycophenolate-natrium (Myfortic®) Therapy Active, not recruiting NCT00978965
34 Pathogenesis of Glomerulosclerosis Active, not recruiting NCT00001392
35 Clinical Significance of Assesment of Serum miRNA-30a in Childhood Nephrotic Syndrome Not yet recruiting NCT03235128
36 Different Histopathological Patterns in Patients With HCV Nephropathy Not yet recruiting NCT03476031
37 Human Urine Sample Collection for Alport Nephropathy Biomarker Studies Terminated NCT01602835

Search NIH Clinical Center for Glomerular Disease

Sources

Genetic Tests for Glomerular Disease

About this section
Sources

Anatomical Context for Glomerular Disease

About this section

MalaCards organs/tissues related to Glomerular Disease:

41
Kidney, Endothelial, Monocytes, T Cells, Bone, Liver, Neutrophil
Sources

Publications for Glomerular Disease

About this section

Articles related to Glomerular Disease:

(show top 50) (show all 2806)
# Title Authors PMID Year
1
Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. 38 88
18776121 2008
2
Pathological spectrum of glomerular disease in patients with renal insufficiency: a single-center study in Northeastern China. 38
31198075 2019
3
Recent advances in risk prediction, therapeutics and pathogenesis of IgA nephropathy. 38
31142099 2019
4
Disease-specific incident glomerulonephritis displays geographic clustering in under-serviced rural areas of British Columbia, Canada. 38
31113679 2019
5
Differential methylation as a diagnostic biomarker of rare renal diseases: a systematic review. 38
31419951 2019
6
Prognostic nomogram and score to predict renal survival of patients with biopsy-proven diabetic nephropathy. 38
31401150 2019
7
Clinical outcomes and effects of treatment in older patients with idiopathic membranous nephropathy. 38
31408925 2019
8
Integrated bioinformatics analysis reveals novel hub genes closely associated with pathological mechanisms of immunoglobulin A nephropathy. 38
31316619 2019
9
Indoxyl sulfate associates with cardiovascular phenotype in children with chronic kidney disease. 38
31428929 2019
10
Methods for Assessing Longitudinal Biomarkers of Time-to-Event Outcomes in CKD: A Simulation Study. 38
31416887 2019
11
Contribution of Electron Microscopy to the Clinicopathologic Diagnosis in Childhood Glomerular Renal Diseases. 38
30942128 2019
12
Cardiovascular disease risk among children with focal segmental glomerulosclerosis: a report from the chronic kidney disease in children study. 38
30903375 2019
13
Accelerated podocyte detachment early after kidney transplantation is related to long-term allograft loss of function. 38
30500951 2019
14
Gene polymorphism and risk of idiopathic membranous nephropathy. 38
31075233 2019
15
Glomerular disease patients have higher odds not to reach quality targets in chronic dialysis compared with CAKUT patients: analyses from a nationwide German paediatric dialysis registry. 38
30843113 2019
16
Genotype-phenotype correlation and prognostic impact in Chinese patients with Alport Syndrome. 38
31144478 2019
17
Obesity is not associated with progression to end stage renal disease in patients with biopsy-proven glomerular diseases. 38
31266462 2019
18
Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation. 38
30910380 2019
19
A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy. 38
31027890 2019
20
Prevalence of Cardiovascular Disease Risk Factors in Childhood Glomerular Diseases. 38
31286821 2019
21
The tetraspanin CD9 controls migration and proliferation of parietal epithelial cells and glomerular disease progression. 38
31341160 2019
22
Novel parietal epithelial cell subpopulations contribute to focal segmental glomerulosclerosis and glomerular tip lesions. 38
31029503 2019
23
Differences in proximal tubular solute clearance across common etiologies of chronic kidney disease. 38
31347660 2019
24
Fibrillary Glomerulonephritis: An Update. 38
31317113 2019
25
Low levels of urinary epidermal growth factor predict chronic kidney disease progression in children. 38
31005273 2019
26
Structural prediction of antibody-APRIL complexes by computational docking constrained by antigen saturation mutagenesis library data. 38
30761651 2019
27
Role of the glucocorticoid receptor in glomerular disease. 38
31166704 2019
28
Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease. 38
31122702 2019
29
TRPC channels: Regulation, dysregulation and contributions to chronic kidney disease. 38
30953689 2019
30
Pediatric Kidney Transplantation: Experience of a Center Over 4 Decades. 38
31155196 2019
31
Renal histopathology of prolonged acute kidney injury in HELLP syndrome: a case series and literature review. 38
30989562 2019
32
Risk Factors for Primary Arteriovenous Fistula Dysfunction in Hemodialysis Patients: A Retrospective Survival Analysis in Multiple Medical Centers. 38
31067537 2019
33
Glucocorticoid induced adrenal insufficiency is common in steroid treated glomerular diseases - proposed strategy for screening and management. 38
31060510 2019
34
The importance of clinician, patient and researcher collaborations in Alport syndrome. 38
31044288 2019
35
De novo mutations in COL4A5 identified by whole exome sequencing in 2 girls with Alport syndrome in Korea. 38
30477285 2019
36
Urine markers of renal tubular injury in idiopathic membranous nephropathy: A cross sectional study. 38
30684459 2019
37
From podocyte biology to novel cures for glomerular disease. 38
31420194 2019
38
Health-related quality of life in glomerular disease. 38
30898342 2019
39
Prevalence and 20-year epidemiological trends of glomerular diseases in the adult Saudi population: a multicenter study. 38
31215222 2019
40
One Actor, Many Roles: Histopathologies Associated With APOL1 Genetic Variants. 38
30624253 2019
41
The Changing Face of Human Immunodeficiency Virus-Mediated Kidney Disease. 38
31202391 2019
42
Prevalence and incidence of kidney diseases leading to hospital admission in people living with HIV in France: an observational nationwide study. 38
31061062 2019
43
Inhibition of the ERK1/2-mTORC1 axis ameliorates proteinuria and the fibrogenic action of transforming growth factor-β in Adriamycin-induced glomerulosclerosis. 38
31377057 2019
44
Effects of Sustained-Release Beraprost in Patients With Primary Glomerular Disease or Nephrosclerosis: CASSIOPEIR Study Results. 38
31119846 2019
45
Collapsing glomerulopathy: update. 38
30554809 2019
46
Serum levels of DNAJB9 are elevated in fibrillary glomerulonephritis patients. 38
31010480 2019
47
Statistical methods for building better biomarkers of chronic kidney disease. 38
30663113 2019
48
Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence. 38
31229276 2019
49
New developments in the diagnosis of fibrillary glomerulonephritis. 38
31227146 2019
50
[Alport syndrome. Report of two cases]. 38
31344217 2019
Sources

Variations for Glomerular Disease

About this section

ClinVar genetic disease variations for Glomerular Disease:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 COL4A5 NM_000495.5(COL4A5): c.1871G> A (p.Gly624Asp) single nucleotide variant Pathogenic rs104886142 X:107842023-107842023 X:108598793-108598793
2 COL4A3 NM_000091.4(COL4A3): c.2657-1G> T single nucleotide variant Uncertain significance rs373324875 2:228148482-228148482 2:227283766-227283766
Sources

Expression for Glomerular Disease

About this section
Search GEO for disease gene expression data for Glomerular Disease.
Sources

Pathways for Glomerular Disease

About this section

Pathways related to Glomerular Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Primary Focal Segmental Glomerulosclerosis FSGS 1
10.79 NPHS2 NPHS1 COL4A5 CD2AP
2
A-beta Pathways: Uptake and Degradation 65
10.76 CCL2 ACE
3
Nephrin/Neph1 signaling in the kidney podocyte 1
10.55 NPHS2 NPHS1 CD2AP
4
Nephrin interactions 66
10.5 NPHS1 CD2AP
Sources

GO Terms for Glomerular Disease

About this section

Cellular components related to Glomerular Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.43 NPHS2 NPHS1 NAGLU CD2AP ALB ACE
2 slit diaphragm GO:0036057 8.62 NPHS2 NPHS1

Biological processes related to Glomerular Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 excretion GO:0007588 8.62 NPHS2 NPHS1
Sources

Sources for Glomerular Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....